Skip to main content
. 2019 Oct 1;10:1235. doi: 10.3389/fphys.2019.01235

FIGURE 2.

FIGURE 2

Expression of AIM2 in CD14+ PBMCs. Flow cytometry analysis was performed on CD14+ cells to evaluate AIM2 expression. (A) No differences in AIM2 expression were detected between CD14+ PBMCs derived from exacerbated and stable COPD patients. (B) Pair-matched samples (n = 8) showed an increased AIM2 expression in stable compared to the corresponding exacerbated condition COPD-derived PBMCs. Data are represented as median ± interquartile range. Statistically significant differences were determined by Mann–Whitney U test.